Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 19, 2018
Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder PerceptionsTing Wang, Neil McAuslane, Lawrence Liberti, et al.
Clinical Therapeutics|April 22, 2021
Transparency in European Medicines Agency and US Food and Drug Administration Decision Making: Is It Possible to Identify the Rationale for Divergences in Approved Indication From Public Assessment Reports?Magda Bujar, Sara Ferragu, Neil McAuslane, et al.
Frontiers in Medicine|November 27, 2025
Assessment of compliance with good review practices by medicine assessors within the Zambia medicines regulatory authorityConstance Sakala Chisha, Stephanie Leigh, Makomani Siyanga, et al.
Drug Discovery Today|March 15, 2017
Factors related to drug approvals: predictors of outcome?Lawrence Liberti, Alasdair Breckenridge, Jarno Hoekman, et al.
International Journal of Technology Assessment in Health Care|September 8, 2020
Benchmarking health technology assessment agencies-methodological challenges and recommendationsTing Wang, Iga Lipska, Neil McAuslane, et al.
Therapeutic Innovation & Regulatory Science|September 1, 2020
Implementation of a Framework for an Abridged Review Using Good Reliance Practices: Optimising the Medicine Regulatory Review Process in South AfricaAndrea Keyter, Sam Salek, Neil McAuslane, et al.
Frontiers in Pharmacology|January 4, 2021
Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics StudyTing Wang, Neil McAuslane, Lawrence Liberti, et al.
Pharmaceutical Medicine|April 19, 2023
Evaluation of Risk-Based Approaches to the Registration of Medicines: Current Status Among African Regulatory AuthoritiesNeil McAuslane, Magda Bujar, Tariro Sithole, et al.
Drug Discovery Today|October 1, 2021
Building HTA insights into the drug development plan: Current approaches to seeking early scientific advice from HTA agenciesTing Wang, Neil McAuslane, Helga Gardarsdottir, et al.
The Oncologist|May 8, 2015
Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing ApplicationsLawrence Liberti, Pieter Stolk, James Neil McAuslane, et al.
Pageof 5